ArticleParasites & vectors2025
Efficacy of Revolution® Plus (selamectin plus sarolaner) against Amblyomma americanum (lone star ticks) in cats.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of a topical combination product, Revolution® Plus, containing selamectin and sarolaner was evaluated for efficacy against Amblyomma americanum ticks in cats.
methodsFour laboratory dose confirmation efficacy studies were conducted in different geographical regions of the USA using three distinct US isolates of A. americanum. In each study, ten domestic short-hair cats were randomly allocated to each treatment group based on pretreatment host-suitability tick counts. Cats were infested with approximately 50 unfed adult ticks on day -2. On day 0, cats received either a topical placebo or a single topical dose of Revolution® Plus at the minimum dosage of 6.0 mg/kg selamectin + 1.0 mg/kg sarolaner. Cats were re-infested with approximately 50 unfed adult ticks each on days 5, 12, 19, 26, and 33. Tick counts (comprising live attached and live free ticks) were conducted at 72 h post-treatment and after each subsequent weekly re-infestation.
resultsNo treatment-related adverse reactions occurred in any study. In all studies, placebo-treated cats maintained adequate infestations for the entire study duration, and cats treated with Revolution® Plus had significantly lower (P < 0.0001) least squares mean live (attached and free) tick counts than placebo-treated cats at all time points for at least 1 month. Revolution® Plus provided a mean of > 90% effectiveness based on least squares means 72 h after treatment of existing infestations, and maintained > 99.1% effectiveness 72 h after re-infestation through at least day 29.
conclusionsA single dose of Revolution® Plus administered topically at the minimum label dose of 6.0 mg/kg selamectin + 1.0 mg/kg sarolaner provided treatment and control of A. americanum on cats for at least 1 month.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.